Remy Luthringer is CEO & President at Minerva Neurosciences, Inc. (NERV). They have made 7 open-market trades across 1 company since 2017, most recently 2023-05-02.
CIK 0001610384
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NERV | 72,635 | $170K |
Shares reported on the most recent Form 4, priced at the 2023-05-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NERV | SELL | 2023-05-01 | 2023-05-02 | $3.84 | $197K | +64.9% | +45.8% | +115.6% |
| NERV | SELL | 2020-12-16 | 2020-12-16 | $2.64 | $3K | -14.4% | +2.7% | +20.5% |
| NERV | SELL | 2019-12-17 | 2019-12-17 | $7.10 | $17K | -0.7% | +31.8% | -24.3% |
| NERV | SELL | 2018-12-17 | 2018-12-18 | $7.46 | $19K | -6.1% | -0.6% | +17.3% |
| NERV | SELL | 2017-12-14 | 2017-12-15 | $5.85 | $13K | +5.8% | +8.3% | +5.8% |
| NERV | SELL | 2017-02-03 | 2017-02-07 | $11.02 | $378K | -1.0% | -15.5% | -32.0% |
| NERV | SELL | 2017-02-03 | 2017-02-07 | $11.02 | $354K | -1.0% | -15.5% | -32.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.